Bone Density Conservation Agents: Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.Bone Density: The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.Bone and Bones: A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.Bone Remodeling: The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.Absorptiometry, Photon: A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION.Bone Resorption: Bone loss due to osteoclastic activity.Bone Development: The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS.Bone Diseases, MetabolicFractures, Bone: Breaks in bones.Radius: The outer shorter of the two bones of the FOREARM, lying parallel to the ULNA and partially revolving around it.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Femur Neck: The constricted portion of the thigh bone between the femur head and the trochanters.Femur: The longest and largest bone of the skeleton, it is situated between the hip and the knee.Bone Diseases: Diseases of BONES.Lumbar Vertebrae: VERTEBRAE in the region of the lower BACK below the THORACIC VERTEBRAE and above the SACRAL VERTEBRAE.Bone Marrow Cells: Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.Bone Regeneration: Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone.Conserved Sequence: A sequence of amino acids in a polypeptide or of nucleotides in DNA or RNA that is similar across multiple species. A known set of conserved sequences is represented by a CONSENSUS SEQUENCE. AMINO ACID MOTIFS are often composed of conserved sequences.Tibia: The second longest bone of the skeleton. It is located on the medial side of the lower leg, articulating with the FIBULA laterally, the TALUS distally, and the FEMUR proximally.Spine: The spinal or vertebral column.Hip: The projecting part on each side of the body, formed by the side of the pelvis and the top portion of the femur.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Bone Transplantation: The grafting of bone from a donor site to a recipient site.Endangered Species: An animal or plant species in danger of extinction. Causes can include human activity, changing climate, or change in predator/prey ratios.Calcium, Dietary: Calcium compounds used as food supplements or in food to supply the body with calcium. Dietary calcium is needed during growth for bone development and for maintenance of skeletal integrity later in life to prevent osteoporosis.Arm Bones: The bones of the free part of the upper extremity including the HUMERUS; RADIUS; and ULNA.Bone Matrix: Extracellular substance of bone tissue consisting of COLLAGEN fibers, ground substance, and inorganic crystalline minerals and salts.Calcaneus: The largest of the TARSAL BONES which is situated at the lower and back part of the FOOT, forming the HEEL.Osteocalcin: Vitamin K-dependent calcium-binding protein synthesized by OSTEOBLASTS and found primarily in BONES. Serum osteocalcin measurements provide a noninvasive specific marker of bone metabolism. The protein contains three residues of the amino acid gamma-carboxyglutamic acid (Gla), which, in the presence of CALCIUM, promotes binding to HYDROXYAPATITE and subsequent accumulation in BONE MATRIX.Population Density: Number of individuals in a population relative to space.Densitometry: The measurement of the density of a material by measuring the amount of light or radiation passing through (or absorbed by) the material.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Diphosphonates: Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.Osteogenesis: The process of bone formation. Histogenesis of bone including ossification.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Pelvic Bones: Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.Evolution, Molecular: The process of cumulative change at the level of DNA; RNA; and PROTEINS, over successive generations.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Bone Substitutes: Synthetic or natural materials for the replacement of bones or bone tissue. They include hard tissue replacement polymers, natural coral, hydroxyapatite, beta-tricalcium phosphate, and various other biomaterials. The bone substitutes as inert materials can be incorporated into surrounding tissue or gradually replaced by original tissue.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Metacarpus: The region of the HAND between the WRIST and the FINGERS.Biodiversity: The variety of all native living organisms and their various forms and interrelationships.Ecosystem: A functional system which includes the organisms of a natural community together with their environment. (McGraw Hill Dictionary of Scientific and Technical Terms, 4th ed)Phylogeny: The relationships of groups of organisms as reflected by their genetic makeup.Bone Morphogenetic Protein 2: A potent osteoinductive protein that plays a critical role in the differentiation of osteoprogenitor cells into OSTEOBLASTS.Alendronate: A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.Bone Demineralization, Pathologic: Decrease, loss, or removal of the mineral constituents of bones. Temporary loss of bone mineral content is especially associated with space flight, weightlessness, and extended immobilization. OSTEOPOROSIS is permanent, includes reduction of total bone mass, and is associated with increased rate of fractures. CALCIFICATION, PHYSIOLOGIC is the process of bone remineralizing. (From Dorland, 27th ed; Stedman, 25th ed; Nicogossian, Space Physiology and Medicine, 2d ed, pp327-33)Osteoclasts: A large multinuclear cell associated with the BONE RESORPTION. An odontoclast, also called cementoclast, is cytomorphologically the same as an osteoclast and is involved in CEMENTUM resorption.Osteoblasts: Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone.Alkaline Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.X-Ray Microtomography: X-RAY COMPUTERIZED TOMOGRAPHY with resolution in the micrometer range.Osseointegration: The growth action of bone tissue as it assimilates surgically implanted devices or prostheses to be used as either replacement parts (e.g., hip) or as anchors (e.g., endosseous dental implants).Bone Morphogenetic Proteins: Bone-growth regulatory factors that are members of the transforming growth factor-beta superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins.Weight-Bearing: The physical state of supporting an applied load. This often refers to the weight-bearing bones or joints that support the body's weight, especially those in the spine, hip, knee, and foot.Species Specificity: The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.Parathyroid Hormone: A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.Sequence Alignment: The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms.Alveolar Bone Loss: Resorption or wasting of the tooth-supporting bone (ALVEOLAR PROCESS) in the MAXILLA or MANDIBLE.Time Factors: Elements of limited time intervals, contributing to particular results or situations.

Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. (1/1450)

OBJECTIVE: The objective of this review is to present the clinical profiles of the once-weekly and once-daily dosing formulations of alendronate and risedronate, the 2 bisphosphonates currently available in the United States for the prevention and treatment of postmenopausal osteoporosis. DATA SOURCE/STUDY SELECTION: Data were obtained from a MEDLINE literature search of all English language articles published between January 1996 and April 2004 using generic names of the bisphosphonates alendronate and risedronate. Results were refined by incorporating terms such as "osteoporosis," "bone mineral density," "fracture risk," and "adverse events." Randomized, controlled trials of once-daily and once-weekly bisphosphonate therapies were selected. Also selected for review were post hoc analyses and extension studies of the original controlled trials, including more recent data from published abstracts from scientific meetings. DATA EXTRACTION: Relevant portions of articles obtained from the literature search were used to summarize the efficacy and tolerability of the 2 therapies. CONCLUSIONS: In prospective trials, both bisphosphonates were effective in reducing vertebral and hip fractures in women with postmenopausal osteoporosis. In the only prospective trial evaluating hip fracture risk reduction as the primary end point, risedronate was effective at reducing hip fracture vs placebo. Both alendronate and risedronate are available in once-weekly formulations that have efficacy and tolerability profiles similar to the once-daily doses. Clinicians should review all available data for both agents as well as the medical history of the patient to make the most appropriate treatment choice.  (+info)

The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus. (2/1450)

Glucocorticoids are widely used in the treatment of lupus patients, and adverse effects, which include osteoporosis and associated fractures, are frequent. Treatment of osteoporosis of young patients should be effective and not harmful to bone growth and remodeling. Bisphosphonates are drugs that decrease the incidence of bone fractures, but their use in juvenile patients is still controversial because of their possible side effects on the growing skeleton. However, recently published studies showed that linear growth continued normally after treatment with these drugs, and there was no excessive suppression of bone remodeling or mineralization defects. Zoledronic acid is a new intravenous bisphosphonate that has been approved by the US FDA for use with hypercalcemia of malignancies and might be an effective treatment for postmenopausal osteoporosis. The authors report a case of a young girl with systemic lupus who developed multiple vertebral collapses due to glucocorticoid therapy, and zoledronic acid was used producing significant clinical and densitometric improvement.  (+info)

Management of androgen-independent prostate cancer. (3/1450)

BACKGROUND: Although androgen withdrawal can control prostate cancer for long periods in many patients, controversy exists regarding management when the tumor becomes androgen independent. Several options are now available. METHODS: A review of the pertinent literature of the last 20 years was conducted to provide guidance in defining and managing hormone-refractory prostate cancer. RESULTS: Stage D prostate cancer can be subclassified to correlate tumor biology with disease stage. Secondary hormone manipulations may induce responses in patients after failure of initial androgen suppression, and chemotherapy with docetaxel has prolonged survival in patients with androgen-independent prostate cancer (AIPC). The weight of evidence supports the maintenance of castrate levels of testosterone in metastatic AIPC. Bisphosphonates decrease skeletal complications. CONCLUSIONS: Secondary hormone therapy, chemotherapy, and bisphosphonate therapy may provide benefits for selected patients. Correlation of disease stage with biologic characteristics of the tumor and host facilitates proper choices of interventions. Docetaxel-based chemotherapy regimens should be considered for first-line treatment of patients with progressive metastatic AIPC.  (+info)

Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats. (4/1450)

Alendronate sodium, an aminobisphosphonate with potent antiresorptive activity, is used in the treatment of postmenopausal osteoporosis. Retinol, as a component of multivitamin preparations, is frequently used especially by elderly people. There are no reports on the interaction of alendronate sodium and retinol. The aim of the present study was to investigate the effect of administration of alendronate sodium and retinol on mechanical properties of the femoral bone in bilaterally ovariectomized rats. The experiments were carried out on 3-month-old Wistar rats, divided into 7 groups: I - sham-operated control rats, II - ovariectomized control rats, III - ovariectomy + alendronate sodium 3 mg/kg po, IV - ovariectomy + retinol 700 IU/kg po, V - ovariectomy + retinol 3500 IU/kg po, VI - ovariectomy + alendronate sodium 3 mg/kg po + retinol 700 IU/kg po, VII - ovariectomy + alendronate sodium 3 mg/kg po + retinol 3500 IU/kg po. The drugs were administered to the rats daily by oral gavage for 28 days. Body mass gain, bone mass, bone mineral content and calcium content in the femur and L-4 vertebra and mechanical properties of the whole femur (extrinsic stiffness, ultimate load, breaking load, deformation caused by the ultimate load) and the neck of the femur (load at fracture), were examined. Bilateral ovariectomy induced osteopenic changes in the rat skeletal system. Alendronate sodium (3 mg/kg po) counteracted the development of osteopenia induced by ovariectomy. Retinol at both used doses unfavorably affected the examined bone parameters of ovariectomized rats. Retinol administered with alendronate sodium lessened the preventive action of alendronate on the development of osteopenic changes in the skeletal system of ovariectomized rats.  (+info)

Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. (5/1450)

Bisphosphonates, which inhibit osteoclasts, alleviate many of the devastating consequences of metastatic bone disease. However, bisphosphonates may play a role in the development of osteonecrosis of the jaws. We report our experience in the management of a patient with a history of bisphosphonate therapy who presented with osteonecrosis of the jaws following dental extraction to make others, particularly the broader dental community, aware of this potential complication. We also review the pharmacologic properties of bisphosphonates and their possible role in the pathophysiology of osteonecrosis. Until more is known about the role of bisphosphonates in the development of osteonecrosis of the jaws, we recommend that measures be taken to prevent osteonecrosis in those at risk, including, when feasible, a dental consultation before initiating bisphosphonate therapy.  (+info)

Effect of adminitration of etidronate and retinol on bone mechanical properties in ovariectomized rats. (6/1450)

The experiments were carried out on rats, divided into 7 groups: I-sham-operated control rats, II-ovariectomized (OVX) control rats, II- OVX+etidronate (10 mg/kg po), IV-OVX+retinol (700 IU/kg po), V-OVX+retinol (3,500 IU/kg po), VI-OVX+etidronate (10 mg/kg po)+retinol (700 IU/kg po), VII-OVX+etidronate (10 mg/kg po)+retinol (3 500 IU/kg po). The drugs were administered once a day for 4 weeks. Bone mass, content of mineral substances and calcium were examined in the femur, tibia and L-4 vertebra. In the femur, mechanical properties of the whole bone supported on its epiphyses (the ultimate load, the breaking load and the deformation caused by the applied load) and of the femoral neck (the load causing the fracture) were studied. Bilateral ovariectomy induced unfavorable changes in mechanical properties of rat bones, which were partially prevented by administration of etidronate. Retinol at 3,500 IU/kg po caused intensification of the osteoporotic changes, especially it worsened the mechanical properties of bones. The results of the present study do not indicate the existence of any interaction between retinol and etidronate concerning mechanical properties of bones in OVX rats.  (+info)

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. (7/1450)

OBJECTIVES: To establish the clinical effectiveness and cost-effectiveness of selective oestrogen receptor modulators, bisphosphonates and parathyroid hormone (subject to licensing) for the prevention and treatment of osteoporosis and the prevention of osteoporotic fractures in postmenopausal women. DATA SOURCES: Electronic databases. REVIEW METHODS: Studies that met the review's entry criteria were eligible for inclusion in the meta-analyses provided that they reported fracture incidence in terms of the number of patients suffering fractures. Meta-analysis was carried out using the random-effects model. A model was constructed to estimate the cost-effectiveness of osteoporosis interventions. The model calculated the number of fractures that occurred and provided the costs associated with osteoporotic fractures, and the quality-adjusted life-years (QALYs). In addition, the conditions of breast cancer and coronary heart disease (CHD) were modelled, as some interventions have been shown to affect the risk of these conditions. RESULTS: Ninety randomised controlled trials (RCTs) met the inclusion criteria. They related to the five interventions (alendronate, etidronate, risedronate, raloxifene and teriparatide) and to five comparators (calcium, calcium plus vitamin D, calcitriol, hormone replacement therapy and exercise), as well as placebo or no treatment. All five interventions have been shown to reduce the risk of vertebral fracture in women with severe osteoporosis with adequate calcium intakes. However, none of these drugs has been demonstrated, by direct comparison, to be significantly more effective than either each other or the other active interventions reviewed in this report. The intervention costs of treating all osteoporotic women, for a period of 5 years, were in the region of pound 900-1500 million for alendronate, etidronate, risedronate and raloxifene. The cost per QALY ratios fell dramatically with age. Assuming the risks of a woman with severe osteoporosis at the threshold of osteoporosis, no treatment had a cost per QALY below pound 35,000 at 50 years of age. At 60 years of age, the cost per QALY of raloxifene was pound 26,000 assuming no impact on hip fractures, and pound 31,000 assuming an adverse effect. However, these results are driven by the effect on breast cancer and the assumptions made regarding this disease state. No other intervention had a cost per QALY below pound 35,000. When analyses were conducted assuming that the fracture risk is doubled at each site, alendronate and risedronate had cost per QALY ratios below pound 30,000 at all ages. For women at the threshold of osteoporosis, without a prior fracture and aged 70 years, the cost per QALY of the three bisphosphonates ranged from pound 34,000 to pound 41,000. Raloxifene had a cost per QALY of pound 23,000, assuming no effect on hip fracture, given assumptions regarding breast cancer. At 80 years of age, the cost per QALY of alendronate and risedronate was below pound 20,000. This was true for etidronate when incorporating observational data, but the value rose to pound 69,000 when only RCT data were used. No other intervention had a cost per QALY below pound 35,000. It was assumed that doubling the risk of fracture for women without a prior fracture would give results similar to patients at the threshold of osteoporosis with a prior fracture. CONCLUSIONS: Of the five interventions, only raloxifene appeared to reduce the risk of vertebral fracture in postmenopausal women unselected for low bone mineral density (BMD). However, as the full data have not been made public, there is some uncertainty regarding this result. None of the five interventions has been shown to reduce the risk of non-vertebral fracture in women unselected for low BMD. All of the proposed interventions provided gains in QALYs compared with no treatment in women with sufficient calcium and vitamin D intakes. The size of the QALY gain for each intervention was strongly related to the age of the patient. The estimated costs varied widely for the interventions. These net costs were markedly different by age, with some interventions becoming cost-saving at higher age ranges in patients with a prior fracture. Areas for future research include: the evidence base for the efficacy of fracture prevention in the very elderly, reanalysis of raloxifene using a dedicated breast cancer and CHD model, and more trials considering the cost-effectiveness of teriparatide.  (+info)

Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. (8/1450)

BACKGROUND: Alendronate has been found to reduce the risk of fractures in postmenopausal women as demonstrated in multiple randomized controlled trials enrolling thousands of women. Yet there is a paucity of such randomized controlled trials in osteoporotic men. Our objective was to systematically review the anti-fracture efficacy of alendronate in men with low bone mass or with a history of prevalent fracture(s) and incorporate prior knowledge of alendronate efficacy in women in the analysis. METHODS: We examined randomized controlled trials in men comparing the anti-fracture efficacy of alendronate to placebo or calcium or vitamin D, or any combination of these. Studies of men with secondary causes of osteoporosis other than hypogonadism were excluded. We searched the following electronic databases (without language restrictions) for potentially relevant citations: Medline, Medline in Process (1966-May 24/2004), and Embase (1996-2004). We also contacted the manufacturer of the drug in search of other relevant trials. Two reviewers independently identified two trials (including 375 men), which met all inclusion criteria. Data were abstracted by one reviewer and checked by another. Results of the male trials were pooled using Bayesian random effects models, incorporating prior information of anti-fracture efficacy from meta-analyses of women. RESULTS: The odds ratios of incident fractures in men (with 95% credibility intervals) with alendronate (10 mg daily) were: vertebral fractures, 0.44 (0.23, 0.83) and non-vertebral fractures, 0.60 (0.29, 1.44). CONCLUSION: In conclusion, alendronate decreases the risk of vertebral fractures in men at risk. There is currently insufficient evidence of a statistically significant reduction of non-vertebral fractures, but the paucity of trials in men limit the statistical power to detect such an effect.  (+info)

Custom Building Products offer quality surface preparation solutions for any tile or stone installation. Learn about Custom 9240.
A new UK study that followed a large number of people found that those who took 10 or more prescriptions for oral bisphosphonates, a group of drugs commonly used to treat the bone disease, were at higher risk of developing esophageal cancer.
This is a two-site, three-arm, open-label, pilot randomized controlled trial of bone anti-resorptive therapy during ART initiation in HIV-infected adults. Thirty (30) treatment-naïve HIV-infected adults initiating eligible first-line ART regimens will be randomized in a 1:1:1 fashion to one of the following three arms:. ...
A very seldom mentioned effect of bisphosphonates (drugs such as Fosamax, Actonel, and Boniva) is that these drugs block very important metabolic pathways. Even if you never took bisphosphonates, you
Results 33 patients who were started on teriparatide treatment between 2011-2015 were identified (29 female and 4 male). Mean age was 76.2 (range 63-92). All had pre-treatment DXA, and 32 (97%) were compliant with recommendations for initiation of teriparatide treatment with respect to DXA (one patient borderline). All 33 patients had a pre-treatment bone profile within acceptable limits before start of treatment (adjusted Calcium, Serum Parathyroid Hormone, Vitamin D level, e-gfr). 28 (84.8%) patients tried one agent before initiation of Teriparatide treatment and 5 (15.2%) patients tried 2 agents. 24 (72.7%) patients completed the full course of recommended treatment. 11 out of 24 patients who completed Teriparatide treatment have had post-treatment DXA. 3 out of 24 patients who completed Teriparatide treatment had a fragility fracture after treatment. ...
There are no data on the use of denosumab in steroid induced osteoporosis. Postmenopausal women with chronic use of Glucocorticoid (GCs) are at high-risk of osteoporotic fractures. Despite bisphosphonate treatment, a certain proportion of high-risk patients using chronic GCs either do not achieve a satisfactory gain in bone mineral density (BMD) or develop new fragility fractures. Thus, more potent osteoporosis treatment is necessary for this subgroup of patients. This prompts the current study which aims to examine the efficacy of denosumab in current users of oral bisphosphonates for Glucocorticoid-induced Osteoporosis (GIOP ...
The options available for effective osteoporosis treatment continue to grow. Because of the large number of treatment options, many clinicians, particularly in primary care, are uncertain about when to start therapy, which drug to use, and when to stop. The issue of when to stop antifracture therapy is now front and center as evidence accumulates that the antifracture benefits of some treatments persist after discontinuation and as patients increasingly voice concerns about possible rare but serious problems linked to osteoporosis treatment, such as atypical femoral fractures, osteonecrosis of the jaw, arrhythmias, and cancer. The decision about when to stop or change osteoporosis treatment is particularly complex and should be influenced by the expected benefits and harms of continued use and at least some information about what to expect after therapy is stopped (also known as resolution-of-effect). A prolonged skeletal resolution-of-effect, characteristic of at least some bisphosphonates, might be
A prospective, randomized and double blind once-monthly oral Ibandronate and Risedronate in post-menopausal osteoporosis leprosy patients
This page provides useful content and local businesses that can help with your search for Osteoporosis Treatments. You will find helpful, informative articles about Osteoporosis Treatments, including 5 Tips for Preventing Osteoporosis. You will also find local businesses that provide the products or services that you are looking for. Please scroll down to find the local resources in Gainesville, GA that will answer all of your questions about Osteoporosis Treatments.
This page provides useful content and local businesses that can help with your search for Osteoporosis Treatment. You will find helpful, informative articles about Osteoporosis Treatment, including Osteoporosis. You will also find local businesses that provide the products or services that you are looking for. Please scroll down to find the local resources in Buckhannon, WV that will answer all of your questions about Osteoporosis Treatment.
This page provides useful content and local businesses that can help with your search for Osteoporosis Treatment. You will find helpful, informative articles about Osteoporosis Treatment, including Osteoporosis. You will also find local businesses that provide the products or services that you are looking for. Please scroll down to find the local resources in Chaska, MN that will answer all of your questions about Osteoporosis Treatment.
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Kimm on once a year osteoporosis medication: Hello~ ZOSTAVAX +65yo + MTX ?? ANSWER: YES ABSOLUTELY DEFINITELY YESTERDAY ! THANKS for topic: Once A Year Osteoporosis Medication
Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than 1 years duration) bisphosphonate use for the treatment of post-menopausal osteoporosis or other benign bone disease is associated with impaired dental healing. A case-control study has been chosen to test the hypothesis as the outcome event rate is likely to be very low. A total of 54 cases will be recruited into the study
Osteoporosis is a disease that affects the bones. As the bones start loosing their usual density they become weaker & are more likely to break. Studies have shown that every one in two women & every one in four men above the age of 50 tend to break bones due to osteoporosis. It can cause serious complications & appropriate measures must be taken to avoid extreme consequences.. There is no exact cure for osteoporosis. The idea of the osteoporosis treatment process is to strengthen the bones in order to protect them. The treatment primarily consists of a combination of drugs and suitable lifestyle changes that help in minimising the rate of bone resorption.. Preventive measures include a modification in the general lifestyle factors, doing more muscle-strengthening exercises and ensuring adequate intake of calcium and vitamin D.The medications used for osteoporosis treatment are anti-resorptive agents. Osteoporosis occurs when the rate of resorption in the bones overtakes the rate of bone ...
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis Ege Can Serefoglu1, Zafer Tandogdu21Kiziltepe Hospital, Department of Urology, Mardin, Turkey; 2Taksim Teaching Hospital, Department of Urology, Istanbul, TurkeyAbstract: Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment
Reclast zoledronic acid - How long is fasting required before reclast (zoledronic acid) is taken? Good news for you! Hi. You DO NOT HAVE TO FAST before, during, or after Reclast (zoledronic acid) being given! Reclast (zoledronic acid) is given intravenously, bypassing the GI tract entirely (unlike the oral bisphosphonates, which require fasting). Bon appetite!
Pharmacologic Profile of Risedronate Like all bisphosphonates, risedronate selectively adsorbs to active bone remodeling sites, where it acts to inhibit osteoclast-mediated bone resorption. Risedronate reduces the risk of fracture by preventing bone loss.10 This action results in increased BMD at fracture-prone skeletal sites, notably the lumbar spine and hip, in postmenopausal women with osteopenia11 or osteoporosis.12,13 It has the same effect in patients initiating14 or receiving15 high-dose, longterm ( 6 months) glucocorticoid therapy (prednisone 7.5 mg/d or equivalent). Pharmacokinetic Properties The pharmacokinetic characteristics of risedronate are summarized in Table 3.8,16-19 Risedronate is absorbed rapidly after oral administration and exhibits linear pharmacokinetics over the oral single-dose range of 5 mg to 30 mg.20 The extent of risedronate absorption is comparable when the dose is taken 30 minutes before breakfast or 2 hours after the evening meal, which may permit dosing ...
MAYWOOD, Ill. - Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study conducted at Loyola University Health System. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone.. "These drugs are potentially harmful when taken for long durations, yet little has been known until now about the length of time osteoporosis patients should go without treatment for this debilitating condition," said Pauline Camacho, MD, study investigator and director of the Loyola University Osteoporosis and Metabolic Bone Disease Center. "Our study demonstrated that bones can remain stable for a number of years after these drugs are discontinued.". Doctors recommend that patients take drug holidays from bisphosphonates after four to five years. These drugs continue to stabilize bones and ...
Osteoporosis medication can be a critical way to prevent bone loss and strengthen your bones. Learn more about osteoporosis treatments in this video.
Dr. Kremer and co-lead author, Dr. Nancy Mayo, worked with colleagues to evaluate data from more than 21,000 women diagnosed with breast cancer. The relationship between use of oral bisphosphonates and development of bone metastases after diagnosis with breast cancer was evaluated in two groups of women: those with early stage, localized, cancer and those whose cancer had spread to lymph nodes. Their findings showed that women with early stage breast cancer who had taken oral bisphosphonates, either before or after diagnosis of their cancer, had a reduced risk of bone metastasis. In addition, their study showed that women with later stage cancer, who took oral bisphosphonates post-diagnosis, also had a significantly reduced risk of bone metastasis. The researchers also established a dose-response relationship with oral bisphophonate use in women with local disease: longer time spent on bisphophonate medication resulted in a greater reduction of bone metastases. "Our study is novel in that it ...
That two word phrase - osteoporosis medications - its so commonplace that most of us dont think much about it. Medications sounds normal, doesnt it? And of course, big pharma
en] Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Clinical Trials as Topic ; Drug Approval/methods ; Female ; Glucocorticoids/adverse effects ; Humans ; Male ; Osteoporosis/chemically induced/drug therapy/prevention & control ; Research Design ; Sex ...
The Bisphosphonates market is mainly driven by the incidence and prevalence rate of bone diseases. The expansion in geriatric population is the major driver for the bisphosphonates market. Ageing people start losing bone density and may suffer from fractures therefore bisphosphonate treatment becomes necessary for such patients. According to the U.S. Department of Health and Human Services, 2013 survey, nearly 14.1% of the U.S. population was aged above 65 years and is increasing rapidly. Another significant factor favorable for the growth of bisphosphonates market is the escalation in the number of women in the post-menopausal stage, who suffer from the weakening bones. The total number of women attaining menopause is estimated to cross 1 bn. by 2025, according to the International Menopause Society the number of menopausal women is higher in the developing. Incidence rate of cancers like myeloma which cause loss of bone density. Bisphosphonates are also used for therapy in the patients ...
With the launch of the first prescription osteoporosis medication 15 years ago, millions of Americans with the bone-thinning disease began taking the drugs and never looked back.. But now many bone-health doctors are looking back and becoming increasingly uneasy.. In the last few years, evidence has emerged that long-term use of osteoporosis drugs - particularly the oldest class of drugs, the bisphosphonates - may do more harm than good.. ...
03 June 2012 Toronto - New research presented today draws a significant link between the development of osteoporosis, osteoporosis treatment and a reduced risk of breast cancer recurrence.. The study was one of a total of 20 abstracts to be presented by the NCIC Clinical Trials Group (CTG) at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The meeting is considered to be the premier scientific event for oncology professionals. The presentations focus on new ways to treat a variety of cancers including breast, colorectal, lung and prostate.. Todays ASCO presentation is an exploratory study within a completed large clinical trial, which involved more than 7,000 postmenopausal breast cancer patients. The objective of the original trial was to compare the use of two aromatase inhibitors (AIs) - exemestane and anastrozole - as adjuvant therapy to determine which was more effective at preventing recurrence of the disease. Adjuvant therapy is used after initial treatment for ...
03 June 2012 Toronto - New research presented today draws a significant link between the development of osteoporosis, osteoporosis treatment and a reduced risk of breast cancer recurrence.. The study was one of a total of 20 abstracts to be presented by the NCIC Clinical Trials Group (CTG) at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The meeting is considered to be the premier scientific event for oncology professionals. The presentations focus on new ways to treat a variety of cancers including breast, colorectal, lung and prostate.. Todays ASCO presentation is an exploratory study within a completed large clinical trial, which involved more than 7,000 postmenopausal breast cancer patients. The objective of the original trial was to compare the use of two aromatase inhibitors (AIs) - exemestane and anastrozole - as adjuvant therapy to determine which was more effective at preventing recurrence of the disease. Adjuvant therapy is used after initial treatment for ...
For osteoporosis patients unable to exercise, help may be on the way. Thats because scientists have discovered precisely how mechanical stress, such as exercise, promotes new bone growth. This opens the door to entirely new therapies that can trick bones into thinking they are getting a workout.
Although oral bisphosphonates (BPs) are highly effective in preventing fractures, some patients will fracture while on treatment. We identified predictors of such fractures in a population-based cohort of incident users of oral BPs. We screened the Sistema dInformació per al Desenvolupament de lInvestigació en Atenció Primària (SIDIAP) database to identify new users of oral BPs in 2006-2007. SIDIAP includes pharmacy invoice data and primary care electronic medical records for a representative 5 million people in Catalonia (Spain). Exclusion criteria were the following: Paget disease; |40 years of age; and any antiosteoporosis treatment in the previous year. A priori defined risk factors included age, gender, body mass index, vitamin D deficiency, smoking, alcohol drinking, preexisting comorbidities, and medications. Fractures were considered if they appeared at least 6 months after treatment initiation. Fractures while on treatment were defined as those occurring among participants persisting
Zoledronic Acid (ZA) is a potent nitrogen-containing bisphosphonates (NBP) has been extensively used to limit bone turnover in a various diseases including tumors. Recently, clinical trails of Zoledronic Acid demonstrated direct anti-cancer effects as well as the known skeletal-related events. We investigated the effect of 4 NBPs on human tumor cells proliferation and found ZA is most potent for GBM cell, breast cell and GBM patients stem-cell-like cells. ZA also effectively inhibited GBM tumor growth in mouse model. ZA stimulated strong autophagy but not apoptotic signals in all tested cells. One intermediate product of cholesterols synthesis pathway--geranylgeranyl diphosphate (GGPP) rescued cell from the cytotoxicity of ZA. Knock-down RABGGTA, which encoded a subunit of the Rab geranylgeranyltransferase proteins, induced a similar effect as Zoledronic Acid in cancer cell lines. These data suggested great potential for Zoledronic Acid against human cancer.. Note: This abstract was not ...
... - Osteoporosis diagnosis usually comes after a fracture or fall, when the weakened bones have caused the damage
Most treatments only slow bone loss. Instead, get the ONLY natural osteoporosis treatment guaranteed to INCREASE bone density. Discover more now!
Zoledronic acid (sometimes called zoledronate) is a bisphosphonate (bis FOS fo nayt) medicine that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. Reclast and Zometa are two different brands of zoledronic acid. Reclast is used to treat osteoporosis...
The worldwide osteoporosis drugs market is predicted to witness a notable growth due to the growing occurrence of osteoporosis along with growing old age population during the estimated period. Availability of technically advanced treatment alternatives combined with growing levels of patient awareness, occurrences of chronic ailments and lifestyle related ailments are further predicted to promote the growth and expansion of the global osteoporosis drugs market.. Browse Full Report Visit - http://www.acutemarketreports.com/report/osteoporosis-drug-market-report. Osteoporosis is a chronic ailment that is featured by reduction in bone mass and bone tissues resulting in bone cracks & fractures. It is also considered as a life threatening ailment owing to serious damage and related pain with it. Few of the factors causing osteoporosis are genetic factors, old age, calcium deficiency, vitamin D deficiency, wrong dietary habits, sedentary/inactive lifestyle, and smoking, low body mass, excessive ...
Medigo lists trusted healthcare providers offering Osteoporosis Treatment. Compare clinics, hospitals, prices, and reviews, and get a free quote.
Oral regimens for the treatment of osteoporosis, mostly oral bisphosphonates, expose only low efficacy due to their relatively high rate of side-effects and adverse events, with very low persistence rates [2] of about 30% and 9% after 1 and 5 years, respectively [3]. The introduction of intravenous bisphosphonates improved persistence and rendered possible for the first time reliable study outcomes on the efficacy and safety of these drugs, particularly of zoledronic acid, as described in the paper by Black and colleagues [1]. Nevertheless, according to a former study, approximately one-third of patients treated with zoledronic acid suffer from post-infusion symptoms such as pyrexia, influenza-like symptoms, myalgia, headache and arthralgia after the first infusion, and the number of patients with arrhythmia or serious atrial fibrillation is significantly higher in the zoledronic acid group than in the placebo group [4]. Such side-effects and adverse events might be one reason for the small ...
Extracted from text ... SA Pharmaceutical Journal - April 2006 40 DRUG INFO Protos(r) - The first of a new class for osteoporosis: dual action bone agent Approved indication Protos(r) contains strontium ranelate and is indicated for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral and peripheral fractures, including the hip. Mode of action Strontium ranelate has a unique pharmacological profile characterised by an inhibition of bone resorption and a simultaneous stimulation of bone formation. It targets the bone remodelling process by stimulating osteoblast-mediated bone formation and by inhibiting osteoclast-mediated bone resorption. The dual mode of action of strontium ranelate may ..
Results Number of the patients were 53 (male: 4 cases, female: 49 cases), and their characteristics at the beginning of denosumab treatment were as below; age: 64.19±12.0 years old, dose of prednisolon: 10.59±9.97mg/day, BMD of lumber spine: 0.768±0.112g/cm3, T-score of lumber spine: -2.28±1.01, BMD of femoral neck: 0.540±0.085g/cm3, T-score of femoral neck: -2.28±0.76. After 2-years denosumab treatment, T-scores of lumber spine (0.54±0.39 gain) and femoral neck (0.13±0.26 gain) were significantly increased from baseline (Figure; mean ± SEM. *:p,0.05). In addition, the serum markers of bone metabolism, both absorption and formation, were significantly suppressed with denosumab. ...
Amgens Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as second-line therapy, mostly in patients who are intolerant to Bisphosphonate. In addition to the treatment of Osteoporosis, there is substantial potential for Denosumab for treating bone loss in patients with cancer. Denosumab market is expected to reach USD 3.8 billion in 2015. ...
The World Health Organization (WHO) defines osteoporosis as a bone density (or bone mass) at least 2.5 standard deviations below peak bone mass (defined as the bone mass achieved by healthy adults aged 18-30 y).
Cheapest risedronate with overnight delivery, Where to purchase risedronate pharmacy, Risedronate store toronto, Risedronate goes generic
Osteonecrosis of the jaw (ONJ) is an emerging condition that has been associated with bisphosphonate use, typically in the context of cancer treatment. Currentl...
Bisphosphonate Therapy for Non-Cancer Pain. Marco Pappagallo, MD Director, Pain Medicine Research & Development Professor, Department of Anesthesiology Mount Sinai School of Medicine, NY. Bone Pain. Slideshow 1326947 by cassius
Bisphosphonates are drugs that can be used to treat men whose prostate cancer has spread to the bones and is no longer responding to hormone therapy. They do not treat the cancer itself but they can help to relieve bone pain. Bisphosphonates may also help to prevent and slow down the breakdown of bone.
Osteonecrosis of the jaw, commonly called ONJ, occurs when the jaw bone is exposed and begins to starve from a lack of blood. As the name indicates (osteo meaning bone and necrosis meaning death), the bone begins to weaken and die, which usually, but not always, causes pain. ONJ is associated with cancer treatments (including radiation), infection, steroid use, or potent antiresorptive therapies that help prevent the loss of bone mass. Examples of potent antiresorptive therapies include bisphosphonates such as alendronate (Fosamax); risedronate (Actonel and Atelvia); ibandronate (Boniva); and denosumab (Prolia). While ONJ is associated with these conditions, it also can occur without any identifiable risk factors.. ...
Alendronate Sodium Hainan is a medicine available in a number of countries worldwide. A list of US medications equivalent to Alendronate Sodium Hainan is available on the Drugs.com website.
A U.S. Food and Drug Administration advisory committee wants the agency to limit the duration of bisphosphonate therapy for treatment of osteoporosis, but the committee could not agree on what that time limit should be.
Osteoporosis is a disease that affects bones, making them lower in density and mineral composition, and more fragile and susceptible to fractures from low impacts. The micro-architecture of the bones of osteoporosis patients changes in a way that makes it more fragile. 80% of osteoporosis patients are women, most of them are in the menopause, … [Read more…]. ...
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF).
Our objective was to determine the effect of prior bisphosphonate exposure on the treatment response to teriparatide. All patients started on teriparatide in our hospital are entered into a database. All patients who had at least 12 months treatment
The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration. Osteoporosis,
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For zoledronic acid, the following should be considered: Allergies Tell your doctor if you have ever had any unusual or allergic reaction to zoledronic acid or other medications used to treat a high blood calcium or osteoporosis. Also tell your doctor and pharmacist if you are allergic to any other substances, such as other drugs, foods, preservatives, or dyes.. Pregnancy Zoledronic acid has not been studied in pregnant women. However, studies in animals have shown that zoledronic acid causes birth defects. Women of childbearing age should avoid becoming pregnant. Before taking this medicine, make sure your doctor knows if you are pregnant or if you may become pregnant.. Breast-feeding It is not known whether zoledronic acid passes into breast milk. Although most medicines pass into breast milk in small amounts, many of them may be used ...
Zoledronic acid is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and Zometa ...
Osteoporosis is a silent disease until it is complicated by fractures. Manage your osteoporosis through proper nutrition and lifestyle changes.
Health, ...MAYWOOD Ill. -- Taking time off from certain osteoporosis drugs may b... These drugs are potentially harmful when taken for long durations ye...Doctors recommend that patients take drug holidays from bisphosphonate...The studys goal was to identify the optimal drug holiday length after...,Taking,a,break,from,osteoporosis,drugs,can,protect,bones,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
U.S. regulators said they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc.s Fosamax and certain thigh bone fractures.
Clinical trials show that there is most likely not a serious link between osteoporosis medication and irregular heartbeat in menopausal women...
A U.S. Food and Drug Administration advisory committee meets Friday to review the safety of a popular class of osteoporosis drugs called bisphosphonates.
Zoledronic acid is an intravenous (IV) bisphosphonate for the treatment of hypercalcemia of malignancy (HCM) providing a higher response rate compared to pamidronate disodium.
The purpose of this trial with Zometa is to investigate the effect ZOMETA 4 mg (zoledronic acid for injection in 100mg solution ) has in preventing asso
Osteoporosis and low bone mass are currently estimated to be a major public health threat for almost 44 million U.S. women and men aged 50 and older. While the...
Take a look at the information provided by Bupa about the symptoms, treatment and prevention of osteoporosis including advice about diet and exercise.
Taking treatment for Osteoporosis- a better way for your bone health. Read symptoms, diagnosis, prevention, exercises etc..better Management and treatment!
Sprawdź ile zapłacisz za lek Alendronate Sodium w aptece, znajdź tańsze zamienniki leku. Określ swoje uprawnienia i sprawdź jakie zniżki Ci przysługują.
Actonel belongs to a class of treatment that is known as bisphosphonates. The most important ingredient in Actonel is risedronate sodium. It can be found in differing quantities of 5mg, 30mg, 35mg, 75mg, or 150mg.. How It Works Bone is constantly being broken down by certain cells known as osteoclasts. It is then rebuilt and reformed by structures called osteoblasts. This is a naturally occurring process. However, in some instances, particularly after women go through menopause, there is a lower amount of estrogen in the body. This can cause more of the bone to be broken down by osteoclasts. This may eventually lead to certain disorders of the bone. While this is most common in women, a similar process can take place in men. Risedronate works by binding to the bone, preventing the calcium from being stripped away. This, in turn, stops the bone density from rapidly diminishing.. Uses. Actonel can be used to prevent the onset of osteoporosis in both males and females. However, it can also be ...
Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities.: Bisphosphonates are endogenous pyrophosphat
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Catalysises teriparatide occupy. Forthwith dual spearhead perfectly pollute. Teriparatide lackeys and tickets forteo forteo after chiefly modish or urgently adaptable haulier.
Free Online Library: Denosumab delivered long-term efficacy.(MUSCULOSKELETAL DISORDERS) by Family Practice News; Health, general Bone density Research Bones Density Health aspects Osteoporosis Drug therapy
Bisphosphonates may be more suited for improving the outlook among patients with lung cancer who have bone metastases compared to palliative ...
Fosamax - The causes, the symptoms, and course of the disease, and its possible prevention by early treatment, are all discussed.
Prolia injection contains the active ingredient denosumab, which is a type of medicine called a human monoclonal antibody. This medicine is used to prevent the breakdown of bone.
wBuyBuy, Global eCommerce platforma, napraviti online prodavnica za besplatno, prodavati proizvode sa 92 jezika, prodavati u cijelom svijetu, kupuju iz svih krajeva svijeta. wBuyBuy Global
Ponúkame kvalitné mikroskopy od svetových výrobcov, mikroskopy pre školy, mikroskopy pre laboratória, mikroskopy za skvelé ceny.
Spletna knjigarna in založba Cangura vam nudi knjige in ostale artikle za zdravje. Izbirate lahko med knjigami za samopomoč in ostalimi koristnimi dodatki.
Spletna knjigarna in založba Cangura vam nudi knjige in ostale artikle za zdravje. Izbirate lahko med knjigami za samopomoč in ostalimi koristnimi dodatki.
vauquelinite confrere inquisitions Dionysiacal mansard Lilydale desterilizing stupefactiveness undertapster chippies Cage cliver linguinis self-esteemingly depopulation lepadoid lungie cancroid nontrial mangolds [email protected] ...
TY - JOUR. T1 - Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. AU - Miller, Paul D.. AU - Delmas, Pierre D.. AU - Huss, Hermann. AU - Patel, Katie M.. AU - Schimmer, Ralph C.. AU - Adami, Silvano. AU - Recker, Robert R.. PY - 2010/10/1. Y1 - 2010/10/1. N2 - The relationship between bisphosphonate-induced bone mineral density (BMD) gains and antifracture efficacy remains to be fully elucidated. Data from two antifracture studies were analyzed. Postmenopausal osteoporotic women received oral (2.5 mg daily, 20 mg intermittent) or intravenous (0.5 mg, 1 mg quarterly) ibandronate. Outcome measures included moving averages plots and logistic regression analyses of the relationship between BMD change and vertebral fracture rate. In moving averages plots, ibandronate-induced BMD gains were consistently associated with decreased fracture rates. In the oral study, total-hip BMD increases at years 2 and 3 and lumbar spine BMD increases ...
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolerability were shown after 1 year. INTRODUCTION: Suboptimal adherence to daily and weekly oral bisphosphonates can potentially compromise therapeutic outcomes in postmenopausal osteoporosis. Although yet to be prospectively shown in osteoporosis, evidence from randomized clinical trials in several other chronic conditions shows that reducing dosing frequency enhances therapeutic adherence. Ibandronate is a new and potent bisphosphonate with antifracture efficacy proven for daily administration and also intermittent administration with a dose-free interval of |2 months. This report presents comparative data on the efficacy and safety of monthly and daily oral ibandronate regimens. MATERIALS AND METHODS: MOBILE is a 2-year, randomized, double-blind,
Alendronate, risedronate, zoledronic acid, denosumab, and teriparatide reduce the risk of vertebral and nonvertebral fractures among postmenopausal women with osteoporosis. Ibandronate and raloxifene reduce the risk of vertebral but not nonvertebral fractures. Alendronate, risedronate, zoledronic acid, and denosumab prevent hip fractures among postmenopausal women with osteoporosis. Risedronate decreases the risk of vertebral and nonvertebral fracture among men with osteoporosis.. Among those treated with glucocorticoids, fracture risk reduction was demonstrated for risedronate and alendronate compared to placebo; and for teriparatide compared to alendronate.. Few studies have compared osteoporosis therapies head-to-head.. Adherence to pharmacotherapy is poor in patients with osteoporosis, as with other chronic conditions. Many factors affect adherence to medications, including dosing frequency, side effects of medications, knowledge about osteoporosis, and cost. Age, prior history of fracture, ...
Keep alendronate sodium tablets and all medicines out of the reach of children. General information about the safe and effective use of alendronate sodium tablets . Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use alendronate sodium tablets for a condition for which it was not prescribed. Do not give alendronate sodium tablets to other people, even if they have the same symptoms you have. It may harm them. This Medication Guide summarizes the most important information about alendronate sodium tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about alendronate sodium tablets that is written for health professionals. For more information, call 1-800-272-5525. What are the ingredients in alendronate sodium tablets ? ...
UNLABELLED Once-weekly alendronate 70 mg and once-weekly risedronate 35 mg are indicated for the treatment of postmenopausal osteoporosis. These two agents were compared in a 12-month head-to-head trial. Greater gains in BMD and greater reductions in markers of bone turnover were seen with alendronate compared with risedronate with similar tolerability. INTRODUCTION The nitrogen-containing bisphosphonates, alendronate and risedronate, are available in once-weekly (OW) formulations for the treatment of postmenopausal osteoporosis. A 12-month, head-to-head study was performed to compare these agents in the treatment of postmenopausal women with low BMD. MATERIALS AND METHODS A total of 1053 patients from 78 U.S. sites were randomized to OW alendronate 70 mg (N = 520) or risedronate 35 mg (N = 533), taken in the morning after fasting. Endpoints included BMD changes over 6 and 12 months at the hip trochanter, total hip, femoral neck, and lumbar spine (LS); percent of patients with predefined levels of
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation Kazuhiro Imai Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan Abstract: Osteoporosis is a skeletal disorder characterized by loss of bone mass, decreased bone strength, and an increased risk of bone fracture. The disease progresses with age, especially in postmenopausal women. Japan is one of the most rapidly aging societies worldwide. Japanese individuals over 65 years of age constituted 23.0% of the population in 2010 and 25.1% to 25.2% as of 2013. The estimated number of people with osteoporosis in Japan is currently 13 million. Bisphosphonates increase bone mineral density by inhibiting osteoclast-mediated bone resorption, thereby reducing the risk of fractures. Alendronate sodium hydrate (alendronate) is a bisphosphonate that potently inhibits bone resorption and is used to treat osteoporosis. Sufficient water is required
Teriparatide is the only anabolic (i.e., bone growing) agent[1] indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of osteoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.[3] It has been FDA-approved since 2002.[4] It is effective in growing bone (e.g., 8% increase in bone density in the spine after one year)[5] and reducing the risk of fragility fractures.[4][6] Osteoporosis medications are generally safe, but some side effects of teriparatide include headache, nausea, dizziness, and limb pain.[4]. One randomized trial of postmenopausal women who had already fractured vertebra compared teriparatide at either 20 or 40 micrograms per day with placebo. After about 19 months, 14% of the women taking placebo had new vertebral fractures, as compared with 5% of the women taking 20 micrograms of teriparatide and 4% of the women taking 40 ...
HCPCS Code: g9769. HCPCS Code Description: Patient had a bone mineral density test in the past two years or received osteoporosis medication or therapy in the past 12 months
In 2009, the global Osteoporosis drug market was worth USD 6.8 billion, with Bisphosphonate class of drugs leading the market. In the overall Bisphosphonate, ibandronate (Bonviva/Boniva; Roche) and zoledronate (Aclasta/Zometa; Novartis) accounted largest share in class, respectively, and showed an average sales growth rate of about of 20% in the past 2 years. Amgens Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the Bisphosphonate drug class. However, initial uptake of Denosumab is likely to be as second-line therapy, mostly in patients who are intolerant to Bisphosphonate. In addition to the treatment of Osteoporosis, there is substantial potential for Denosumab for treating bone loss in patients with cancer. Denosumab market is expected to reach USD 3.8 billion in 2015. Our research indicates that the ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Osteoporosis Drugs Market is expected to witness growth of international market with respect to advancements and innovations including development history, competitive analysis and regional development forecast.. The report starts with a basic Osteoporosis Drugs market overview. In this introductory section, the research report incorporates analysis of definitions, classifications, applications and industry chain structure. Besides this, the report also consists of development trends, competitive landscape analysis, and key regions development status.. The Osteoporosis Drugs market research report shed light on Foremost Regions like:. North America, Europe, China, Japan, Southeast Asia and India. Classification likes Antiresorptive Medications and Anabolic Medications. Application likes Hospital use and Clinic use. Browse Detailed TOC, Tables, Figures, Charts and Companies Mentioned in Osteoporosis Drugs Market ...
Bisphosphonates are the major treatment of choice for osteoporosis, given that they are attached preferentially by bone and significantly reduce the risk of fractures. Oral bisphosphonates are poorly absorbed (usually less than 1% for nitrogen-containing bisphosphonates) and when taken with food or beverages create complexes that cannot be absorbed. For this reason, they must be taken on an empty stomach, and a period of up to 2 hours must elapse before the consumption of any food or drink other than plain water. This routine is not only inconvenient but can lead to discontinuation of treatment, and when mistakenly taken with food, may result in misdiagnosis of resistance to or failure of treatment. The development of an enteric-coated delayed-release formulation of risedronate with the addition of the calcium chelator, ethylenediaminetetraacetic acid (EDTA), a widely used food stabilizer, eliminates the need for fasting without affecting the bioavailability of risedronate or its efficacy.
What were presenting here is the first presentation of a very large double-blind randomised trial comparing the use of zoledronic acid, which is kind of the standard of care for the treatment of myeloma related bone disease, to denosumab which is a monoclonal antibody directed against RANK ligand. It is the first time we are presenting this dataset; it is one of the largest multi-centre international trials of close to a little over 1,700 patients actually, so one of the largest international trials that we are presenting in myeloma. The other nice thing about this trial is all of these patients, in fact, the eligibility was that these are newly diagnosed patients comparing standard of care of zoledronic acid with denosumab as bone targeted treatment for myeloma.. What methods did you use?. Like I said, this was a double blind randomised trial; we have over 1,700 patients in this trial. It was a one to one randomisation with half the patients getting zoledronic acid plus placebo versus the ...
NEW ORLEANS, LA - Bisphosphonate treatments, proven to enhance bone density and reduce fracture incidence in post-menopausal women, may adversely affect bone quality and increase risk of atypical fractures of the femur when used for four or more years, according to preliminary research presented today at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).. Bisphosphonates are designed to slow or stop the bone loss that occurs during the bodys bone remodeling cycle, or the natural process that involves removal and replacement of bone tissue.. Two separate studies by researchers from Hospital for Special Surgery (HSS) and Columbia University Medical Center revealed data suggesting that long-term suppression of bone remodeling by bisphosphonate treatments may alter the material properties of bone, potentially affecting the bones mechanical integrity and potentially contributing to the risk of atypical fractures.. "Although bisphosphonates have demonstrated an ...
Zion Market Research has published a new report titled "Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021". According to the report, the global osteoporosis drugs market was valued at approximately USD 11.20 billion in 2015 and is expected to reach approximately USD 14.30 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021.. Osteoporosis is a bone disease in which a fragile bone with an increased susceptibility to fracture. Bones that commonly fracture include the backbones, the bones of the forearm, and the hip. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps. Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of ...
Zion Market Research has published a new report titled "Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021". According to the report, the global osteoporosis drugs market was valued at approximately USD 11.20 billion in 2015 and is expected to reach approximately USD 14.30 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021.. Osteoporosis is a bone disease in which a fragile bone with an increased susceptibility to fracture. Bones that commonly fracture include the backbones, the bones of the forearm, and the hip. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps. Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of ...
Zion Market Research has published a new report titled "Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) and Selective Estrogen Receptor Modulators (SERMs)) for Male and Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021". According to the report, the global osteoporosis drugs market was valued at approximately USD 11.20 billion in 2015 and is expected to reach approximately USD 14.30 billion by 2021, growing at a CAGR of around 4.0% between 2016 and 2021.. Osteoporosis is a bone disease in which a fragile bone with an increased susceptibility to fracture. Bones that commonly fracture include the backbones, the bones of the forearm, and the hip. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps. Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of ...
The geminal bisphosphonates are a new class of drugs characterised by a P-C-P bond. Consequently, they are analogues of pyrophosphate, but are resistant to chemical and enzymatic hydrolysis. The bisphosphonates bind strongly to hydroxyapatite crystals and inhibit their formation and dissolution. This physicochemical effect leads in vivo to the prevention of soft tissue calcification and, in some instances, inhibition of normal calcification. The main effect is to inhibit bone resorption, but in contrast to the effect on mineralisation, the mechanism involved is cellular. These various effects vary greatly according to the structure of the individual bisphosphonate. The half-life of circulating bisphosphonates is very brief, in the order of minutes to hours. 20% to 50% of a given dose is taken up by the skeleton, the rest being excreted in the urine. The half-life in bone is far longer and depends upon the turnover rate of the skeleton itself. Bisphosphonates are very well tolerated; the ...
In QResearch 4.6% of cases and 4.5% of controls had one or more prescriptions for bisphosphonates, as did 4.8% and 4.6%, respectively, in CPRD. About two thirds of patients with a diagnosis of osteoporosis had been prescribed bisphosphonates (64% of cases and 65% of controls in QResearch and 61% and 60%, respectively, in CPRD) and 2% of cases and controls in both databases had prescriptions for bisphosphonates without records of osteoporosis. Bisphosphonate users were more likely to be women and to have a lower BMI. Upper gastrointestinal problems were slightly more common (QResearch: cases 25% in users v 22% in non-users, controls 25% v 20%; CPRD: cases 35% v 29%, controls 33% v 27%) and use of acid lowering drugs was much more common in bisphosphonate users (QResearch: cases 62% in users v 37% in non-users, controls 61% v 32; CPRD: cases 65% v 39%, controls 63% v35%). Among bisphosphonate users, the proportion of patients with rheumatoid arthritis was more than five times higher than in ...
CAS# 121268-17-5 Description of Alendronate sodium: Alendronate sodium is the sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced.
Background: Zoledronic acid is very widely used in patients with metastatic bone disease and osteoporosis. Only one case of bilateral uveitis was recently reported related to its use. Case presentation: We report the first case of severe unilateral anterior uveitis in a patient with breast cancer and an intraocular lens. Following zoledronic acid infusion, the patient developed severe and dramatic right eye pain with decreased visual acuity within 24 hours and was found to have a fibrinous anterior uveitis of moderate severity. The patient was treated with topical prednisone and atropine eyedrops and recovered slowly over several months. Conclusions: Internists, oncologists, endocrinologists, and ophtalmologists should be aware of uveitis as a possible complication of zoledronic acid therapy. Patients should be instructed to report immediately to their physicians and treatment with topical prednisone and atropine eyedrops should be instituted immediately at the onset of symptoms. This report ...
Importance: A proof-of-principle study suggested that intravenous zoledronic acid may reduce knee pain and the size of bone marrow lesions in people with knee osteoarthritis, but data from large trials are lacking. Objective: To determine the effects of intravenous zoledronic acid on knee cartilage volume loss in patients with symptomatic knee osteoarthritis and bone marrow lesions. Design, Setting, and Participants: A 24-month multicenter, double-blind placebo-controlled randomized clinical trial conducted at 4 sites in Australia (1 research center and 3 hospitals). Adults aged 50 years or older with symptomatic knee osteoarthritis and subchondral bone marrow lesions detected by magnetic resonance imaging (MRI) were enrolled from November 2013 through September 2015. The final date of follow-up was October 9, 2017. Interventions: Intravenous infusion with either 5 mg of zoledronic acid in a 100-mL saline solution (n = 113) or a placebo saline solution (n = 110) at baseline and 12 months. Main ...
To determine if a patient has glucocorticoid-induced osteoporosis, you can measure the bone mineral density (BMD) at different parts of the patients body, such as the spine and hip. Dual energy X-ray absorptiometry (DXA) is currently the best test to measure BMD. The test is quick and painless; it is similar to having an X-ray taken, but uses much less radiation. DXA results are scored in comparison to the BMD of young, healthy individuals, resulting in a measurement called a T-score. Patients with T-scores of -2.5 or lower are considered to have osteoporosis and are at a higher risk for a fracture.. According to patient fact-sheet writer Shreyasee Amin, MD, "the major goal in the management of glucocorticoid-induced osteoporosis is the prevention of fractures and to help decrease bone loss." At a minimum, she suggests that "patients should take 1,000 to 1,500 milligrams of calcium and 400 to 800 IU of vitamin D supplements on a daily basis.". ...
Bisphosphonate-associated osteonecrosis of the jaw (BON, BONJ) is death of the jawbone in a person with a history of bisphosphonate use who undergoes subsequent dental surgery. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy. An association between history of bisphosphonate use and osteonecrosis of the jaw after later surgery was detected for several years and its cause is still not entirely clear. BON has been nicknamed "bis-phossy jaw" based on its similarity with phossy jaw. There is no known prevention for bisphosphonate-associated osteonecrosis of the jaw. Avoiding the use of bisphosphonates is not a viable preventive strategy on a general-population basis because the medications are beneficial in the treatment and prevention of osteoporosis (including prevention of bony fractures) and treatment of bone cancers. Osteonecrosis, or localized death of bone tissue, of the jaws is a ...
The local renin-angiotensin system (RAS) is closely related to bone metabolism. However, it is unknown whether the local RAS is related to bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIOP). Here, we revealed that the two main characteristics of GIOP might inhibit bone formation and enhance bone resorption. INTRODUCTION: The aim of this study is to assess the expression of the main RAS components in the trabecular bone of lumbar vertebrae in GIOP and analyze the relationship between the major RAS components and BMD. METHODS: We collected 96 inpatient cases of lumbar disc herniation from patients who underwent dual-energy X-ray absorptiometry examinations followed by surgical treatment in our hospital. Patients were divided into the GIOP group (n = 48) and control group (n = 48). The circulating and local expression levels of the main RAS components were examined. The correlation between the main RAS components and BMD was then analyzed. RESULTS: The mRNA expression of local ...
BACKGROUND: Parathyroid hormone increases bone strength primarily by stimulating bone formation, whereas antiresorptive drugs reduce bone resorption. We conducted a randomized, double-blind clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent administration of the two agents would increase bone density more than the use of either one alone. METHODS: A total of 238 postmenopausal women (who were not using bisphosphonates) with low bone mineral density at the hip or spine (a T score of less than -2.5, or a T score of less than -2.0 with an additional risk factor for osteoporosis) were randomly assigned to daily treatment with parathyroid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and were followed for 12 months. Bone mineral density at the spine and hip was assessed by dual-energy x-ray absorptiometry and quantitative computed tomography. Markers of bone turnover were measured in fasting blood samples.
BACKGROUND: Docetaxel (DTX) and zoledronic acid (ZOL) are effective in patients with hormone resistant prostate cancer (HRPC) with bone metastases. A phase I clinical trial of metronomic administration of Zoledronic Acid AN d TaxoterE combination (ZANTE trial) in 2 different sequences was conducted in HRPC. RESULTS: The maximum tolerated dose was not achieved with sequence A. Two patients at third level of sequence B developed dose limiting toxicity. A disease control was obtained in six out of nine patients treated with sequence A, where a decrease of biological markers and PSA were also observed. No evidence of anti-tumor activity was observed in patients treated with sequence B. PATIENTS AND METHODS: Twenty-two patients enrolled into the study (median age: 73 years; range: 43-80) received one of three escalated doses of DTX (30, 40 and 50 mg/m(2)) in combination with a fixed dose of ZOL (2 mg), both administered every 14 days in two different sequences: DTX at the day 1 followed by ZOL at the ...
... spermatogenesis-blocking agents MeSH D27.505.696.207 --- astringents MeSH D27.505.696.242 --- bone density conservation agents ... bone cements MeSH D27.720.102.187 --- cariogenic agents MeSH D27.720.102.223 --- cariostatic agents MeSH D27.720.102.339 --- ... anti-allergic agents MeSH D27.505.954.122 --- anti-infective agents MeSH D27.505.954.122.085 --- anti-bacterial agents MeSH ... antiviral agents MeSH D27.505.954.122.388.077 --- anti-retroviral agents MeSH D27.505.954.122.388.077.088 --- anti-hiv agents ...
At night when he sets up camp, Thor eats the meat of the goats, but takes care that all bones remain whole. Then he wraps the ... They have been described as "eating machines" and "biological control agents". There has been a resurgence of this in North ... This form of using goats to clear land is sometimes known as conservation grazing. Since then, numerous public and private ... density, uniformity, fineness, and general body confirmation. Disqualifications include: a deformed mouth, broken down pasterns ...
... as well as chemical expansion agents to decrease the density of the finished product One differentiates between interior and ... Plaster is widely used as a support for broken bones; a bandage impregnated with plaster is moistened and then wrapped around ... Practical Building Conservation. Mortars, Renders & Plasters. Farnham / Burlington: Ashgate. p. 87. Franz Wirsching "Calcium ... In medicine plaster orthopedic casts are still often used for supporting set broken bones. In dentistry plaster is used to make ...
Biological Conservation 163 (2013): 49-57. Jeschke, J., et. al. "Defining the Impact of Non-Native Species." Conservation ... Fewer species were found along the first road with density estimates being almost 80% lower than at the second site that which ... The results suggested that higher levels of fragmentation within the fish-bone pattern led to the loss of species and decreased ... If seed dispersal agents are targeted by hunters, the effectiveness and amount of dispersal for those plant species will be ...
They have been described as "eating machines" and "biological control agents".[57][58] There has been a resurgence of this in ... When a farmer's son who is invited to share the meal breaks one of the goats' leg bones to suck the marrow, the animal's leg ... This form of using goats to clear land is sometimes known as conservation grazing. Since then, numerous public and private ... density, uniformity, fineness, and general body confirmation. Disqualifications include: a deformed mouth, broken down pasterns ...
... bone density, and the proliferation of endometrial cells. miR-181 could acquire a resistance to tamoxifen, the drug is ... Tamoxifen acts as an anti-estrogen (inhibitor) in breast tissue, but as an estrogen (stimulating agent) in cholesterol ... "Conservation of small RNA pathways in platypus". Genome Research. 18 (6): 995-1004. doi:10.1101/gr.073056.107. PMC 2413167 . ... It has been shown that miR-181 is preferentially expressed in the B-lymphoid cells of mouse bone marrow, but also in the retina ...
Affected high-density populations suffered up to 100% mortality in 12-18 months. Between 1996 and 2015, the population dwindled ... Oocyte banking be useful in the conservation effort for Tasmanian devils, as the survival rate of cryopreserved oocytes in is ... The theory that cancer cells themselves could be an infective agent (the Allograft Theory) was first offered in 2006 by Pearse ... Tumours are locally aggressive, destroying the underlying bone of the jaw which interfers with feeding. Tumours may also cover ...
Decellularized allografts have been critical in bone grafts that function in bone reconstruction and replacing of deformed ... Proper conservation of ECM fibers, growth factors, and other proteins is imperative to the progenitor cells differentiating ... EDTA is a chelating agent that binds calcium, which is a necessary component for proteins to interact with one another. By ... The success of decellularization varies based on the components and density of the applied tissue and its origin. The ...
Predators need not eat prey entirely; for example, some predators cannot digest bones. Some may eat only part of an organism, ... Introduction or removal of this predator, or changes in its population density, can have drastic cascading effects on the ... "Bird Predation as a Selective Agent in a Butterfly Population." Evolution 39.1 (1985): 93-103. Conner, W. E. (2009). Tiger ... Besides their use in conservation biology, predators are also important for controlling pests in agriculture. Natural predators ...
Diagnosis of brucellosis relies on: Demonstration of the agent: blood cultures in tryptose broth, bone marrow cultures. The ... Since concentrating animals around food plots accelerates spread of the disease, management strategies to reduce herd density ... Conservation Biology. 8 (3): 645-653. doi:10.1046/j.1523-1739.1994.08030645.x. JSTOR 2386505. CS1 maint: Uses authors parameter ... agent US) Bovine brucellosis (agent AA) Caprine brucellosis (agent AM) Agent US was in advanced development by the end of World ...
Some other bone matrix proteins such as osteopontin and bone sialoprotein use both the first and the second. Direct activation ... Its density of 1.55 g/cm3 is the lowest in its group.[5] Calcium is harder than lead but can be cut with a knife with effort. ... It is also used as a reducing agent in the production of chromium, zirconium, thorium, and uranium. It can also be used to ... so the decay is forbidden by the conservation of angular momentum. While two excited states of 48Sc are available for decay as ...
... and years for bone.[21] Lead in the bones, teeth, hair, and nails is bound tightly and not available to other tissues, and is ... A chelating agent is a molecule with at least two negatively charged groups that allow it to form complexes with metal ions ... conservation programs exist which routinely capture condors, check their blood lead levels, and treat cases of poisoning.[242] ... Its density, workability, and corrosion resistance were among the metal's attractions.[142] ...
Byssal threads, used to anchor mussels to substrates, are now recognized as superior bonding agents. A number of studies have ... Williams, James D.; Jr, Melvin L. Warren; Cummings, Kevin S.; Harris, John L.; Neves, Richard J. (1993-09-01). "Conservation ... where the most common method is to attach mussels to ropes which are hung from a rope back-bone supported by large plastic ... from areas where they have settled naturally to areas where they can be placed in lower densities to increase growth rates, ...
It is due to the scanner being unable to differentiate between a small amount of high-density material (e.g., bone) and a ... The contrast agent may induce contrast-induced nephropathy.[15] This occurs in 2 to 7% of people who receive these agents, with ... Payne, Emma Marie (2012). "Imaging Techniques in Conservation". Journal of Conservation and Museum Studies. 10 (2): 17-29. doi: ... The old radiocontrast agents caused anaphylaxis in 1% of cases while the newer, lower-osmolar agents cause reactions in 0.01- ...
The identity of the bacterial agent remains unknown. Vitamin E, fluoride, and iodide protect against bone loss associated with ... Population densities are usually below 10 per ha (four per acre) and home ranges vary from 0.23 to 0.37 ha (0.57 to 0.91 acres ... The 2016 IUCN Red List assesses the conservation status of the marsh rice rat as "Least Concern", because it is a common, ... The nasal and premaxillary bones extend back beyond the point where the lacrimal, frontal, and maxillary bones meet. In P. o. ...
Otoliths - calcareous deposits or bones found in chambers at the base of the skull in fish. Sectioned, these bones often show ... the International Union for the Conservation of Nature and Natural Resources is the world's main authority on the conservation ... Species density - the number of species in a sampled area. Species group - a group of similar species. Similar species are ... Alginate production - a gel substance extracted from brown algae and used industrially as a thickening agent for food and paint ...
The population density was 48.9 inhabitants per square mile (18.9/km2). There were 8,285 housing units at an average density of ... Banner C. Brummett was appointed County Agent to lay out Nashville in lots to be sold at auction. It was expected that money ... Elkinsville, IN Quadrangle N3900 W8615 /7.5 Field Check 1947 Drainage Map of Brown County, Department of Conservation, State of ... Bean Blossom Belmont Camp Roberts Christiansburg Clarksdale Cornelius Elkinsville Fruitdale Gatesville Gnaw Bone Helmsburg ...
Many other agents contribute, from earthworms to humans as well as the charring process. If biochar becomes widely used for ... Blood, bone meal and chicken manure are useful for short term organic manure addition. Perhaps the most important and unique ... Some ants are repelled from fresh terra preta, their density of appearance is found to be low after about 10 days as compared ... a notion with dramatic implications worldwide for agriculture and conservation. Terra preta sites are also known in Ecuador, ...
Bone disease. As calcium is required for bone development, many bone diseases can be traced to the organic matrix or the ... Its density of 1.55 g/cm3 is the lowest in its group.[7] Calcium is harder than lead but can be cut with a knife with effort. ... It is also used as a reducing agent in the production of chromium, zirconium, thorium, and uranium. It can also be used to ... so the decay is forbidden by the conservation of angular momentum. While two excited states of 48Sc are available for decay as ...
Seedikkoya, K.; Azeez, P.A.; Shukkur, E.A.A. (2007). "Cattle egret as a biocontrol agent" (PDF). Zoos' Print Journal. 22 (10): ... In the dryer habitats with fewer amphibians the diet may lack sufficient vertebrate content and may cause bone abnormalities in ... Kushlan, James A.; Hafner, Heinz (2000). Heron Conservation. Academic Press. pp. 64-65. ISBN 0-12-430130-4. Santharam, V. (1988 ... "Status and distribution of breeding cattle egret and little egret in Amroha using density method" (PDF). Current Science. 88 ( ...
One mechanism by which this occurs in mammals is via the low-density lipoprotein receptor-related protein (LRP), which binds to ... Journal of Bone and Mineral Research. 26 (12): 2798-803. doi:10.1002/jbmr.487. PMC 3214246 . PMID 21826736. Fay WP, Parker AC, ... "Serpin genes AtSRP2 and AtSRP3 are required for normal growth sensitivity to a DNA alkylating agent in Arabidopsis". BMC Plant ... implications of patterns of amino acid conservation for structure and function". Genome Research. 10 (12): 1845-64. doi:10.1101 ...
Sathyakumar in Asiatic Black Bear Conservation Action Plan, chapter 10 of Bears: Status Survey and Conservation Action Plan ... However, the jaws of bears are controlled by large muscles that are capable of crushing bones, which gives access to the ... probably due in part to the density of population and competition for food sources. One specimen, known as the sloth bear of ... contamination from the environment is highly likely and means there is risk for tetanus and other external microbial agents. ...
Paleontological finds in the area have yielded bones of mammoths, saber-toothed cats and other ancient animals, as well as ... The scientific housekeeping movement, promoted across the land by the media and government extension agents, as well as county ... the density standard Frederick Jackson Turner used to declare the American frontier "closed" in 1893. Many have fewer than 2 ... Bison hunting Llano Estacado Great American Desert Great bison belt Great Plains Art Museum Great Plains Conservation Program ...
As in many other aquatic and semiaquatic vertebrates, the bones show osteosclerosis, increasing their density to provide ... The Biodiversity Conservation Branch at the Department of Primary Industries and Water are collaborating with NRM north and ... is a secret agent. The choice of a platypus was inspired by media underuse, as well as to exploit the animal's striking ... As in all true mammals, the tiny bones that conduct sound in the middle ear are fully incorporated into the skull, rather than ...
The partnership of John and George Harris, general merchants and shipping agents, was established in 1853, with the firm ... The Undue Subdivision of Land Prevention Act 1885, introduced to avoid "slum" conditions in areas of medium density dwellings, ... Artefacts within this area may include those commonly associated with domestic habitation such as glass, ceramics and bone, and ... Allom Lovell Architects, Harris Terrace: A conservation plan for the Department of Public Works, 2002, p.3. Allom Lovell ...
Yamada Y, Ando F, Shimokata H (July 2005). "Association of polymorphisms in CYP17A1, MTP, and VLDLR with bone mineral density ... There is a high level of conservation within the LDL receptor family. In particular, there is 50% overall sequence homology ... In trophoblast-derived cell lines, up-regulated VLDLR expression occurs when cells are incubated with hypolipidemic agents such ... The very-low-density-lipoprotein receptor (VLDLR) is a transmembrane lipoprotein receptor of the low-density-lipoprotein (LDL) ...
S. N. Stuart; Richard J. Adams (1990). Biodiversity in Sub-Saharan Africa and its Islands: Conservation, Management and ... French troops occupied the fort despite protests from the British Agent in Aden, Major Frederick Mercer Hunter, who dispatched ... Long-horned humpless cattle bones have likewise been discovered at Asa Koma, suggesting that domesticated cattle were present ... Density. 37.2/km2 (96.3/sq mi) (168th). GDP (PPP). 2018 estimate. ...
... the bones show osteosclerosis, increasing their density to provide ballast.[25] It has a reptilian gait, with the legs on the ... The Biodiversity Conservation Branch at the Department of Primary Industries and Water are collaborating with NRM north and ... is a secret agent. The choice of a platypus was inspired by media underuse, as well as to exploit the animal's striking ... However, the external opening of the ear still lies at the base of the jaw.[15] The platypus has extra bones in the shoulder ...
Bone Density Conservation Agents/therapeutic use*. *Drug Prescriptions/statistics & numerical data. *Drug Utilization/ ... Bone Density Conservation Agents. Grant support. *MR/K006665/1/Medical Research Council/United Kingdom ...
Antineoplastic Agents, Hormonal. Selective Estrogen Receptor Modulators. Estrogen Receptor Modulators. Bone Density ... Patient must have either measurable disease or If no measurable disease is present, then at least one predominantly lytic bone ... Antineoplastic Agents. Aromatase Inhibitors. Steroid Synthesis Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Patient is currently using other antineoplastic agents. *Patient is pregnant or nursing or physiologically capable of becoming ...
Bone Density Conservation Agents. To Top. *For Patients and Families. *For Researchers ...
PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and ... Bone Density Conservation Agents. *Bone Density Conservation Agents: therapeutic use. *Bone Neoplasms ... PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and ...
Bone Density Conservation Agents. Calcium-Regulating Hormones and Agents. To Top. *For Patients and Families ...
Bone Density Conservation Agents. Anticholesteremic Agents. Hypolipidemic Agents. Antimetabolites. Molecular Mechanisms of ... Lipid Regulating Agents. Hydroxymethylglutaryl-CoA Reductase Inhibitors. Enzyme Inhibitors. Antihypertensive Agents. Calcium ... Calcium-Regulating Hormones and Agents. Physiological Effects of Drugs. ...
Bone Density Conservation Agents. *Calcium-Regulating Hormones and Agents. *Cholecalciferol, antagonists & inhibitors ... and bone metabolism [A223, L5689, L1782, L5771, F4027, F4042, F4048]. However, studies are also ongoing to determine whether or ... which makes vitamin D3 the preferred agent for medical use [L5689]. Appropriate levels of vitamin D must be upheld in the body ...
bone density conservation agent An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. ... calcitriol (CHEBI:17823) has role bone density conservation agent (CHEBI:50646) calcitriol (CHEBI:17823) has role calcium ... Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. ... Agents that increase calcium influx into calcium channels of excitable tissues.. human metabolite Any mammalian metabolite ...
Bone Density Conservation Agents/therapeutic use*. *Bone and Bones/drug effects. *Bone and Bones/metabolism ... which leads to enhanced osteoblastic bone formation. LRP5=low-density lipoprotein receptor-related protein 5. FZD=frizzled. DSH ... to one driven by advances in fundamental bone biology (eg, denosumab) coupled with clues from patients with rare bone diseases ... Osteoblastic functions and bone formation is reduced. (C) Antibodies against sclerostin or DKK-1, or both, neutralise the Wnt ...
... and trabecular bone score (TBS) in hypoparathyroidism over a 2-yea... ... Bone Density Conservation Agents. Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. ... Lumbar Spine Bone Mineral Apparent Density in Children: Results from the Bone Mineral Density in Childhood Study. ... Bone Mineral Density in Pediatric Epilepsy. What are the effects of the currently used AEDs on bone mineralization in children ...
... clinicaltrials.gov Bone density was found to be impaired among lage babies and infants of diabetic mothers as found in small ... Bone Density Conservation Agents. Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. ... on bone mineral density and bone metabolism p.... Comparison of bone turnover markers in peripheral blood and bone marrow ... It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS. ...
Bone Density Conservation Agents / blood * Bone Density Conservation Agents / pharmacokinetics* * Bone Density Conservation ...
0/Bone Density Conservation Agents; 0/Calcium, Dietary From MEDLINE®/PubMed®, a database of the U.S. National Library of ... Bone Density Conservation Agents / administration & dosage*. Calcium, Dietary / administration & dosage*. Cross-Sectional ... Previous Document: Cocoa flavanol-enriched snack bars containing phytosterols effectively lower total and low-density l.... ...
Bone Density / drug effects, physiology. Bone Density Conservation Agents / administration & dosage*. Diphosphonates / ... 0/Biological Markers; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Peptide Fragments; 0/Procollagen; 0/procollagen ... 14987325 - Transdermal hormone replacement therapy improves vertebral bone density in primary bili.... 15235345 - Effectiveness ... and bone mineral density (BMD). Fifty-two patients had been treated for at least 12 months, 38 with prior bisphosphonate ...
0 (Adaptor Proteins, Signal Transducing); 0 (Biomarkers); 0 (Bone Density Conservation Agents); 0 (Proteins); 0 (SQSTM1 protein ... In 1982, Prusiner investigated the infectious fraction of scrapie-infected brain homogenate, defined the infectious agent as ... The infectious agent was supposed to be a novel virus, so TSE was classified into slow virus infection. ...
0 (Antioxidants); 0 (Biomarkers); 0 (Bone Density Conservation Agents); 0 (Isoflavones); 1C6V77QF41 (Cholecalciferol); EC 3.4. ... 0 (Anti-Bacterial Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Antioxidants); 0 (Chlorides); 0 (Ferric Compounds); 0 ( ... 0 (Anti-Inflammatory Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Antioxidants); 0 (Plant Extracts). ... In this context, we assayed the activities of several inflammation and bone homeostasis mediators, such as IL-6, TNFα, PGE2, ...
... a creative approach to precisely estimate the risk of hip fracture by exploring the relationship between hip fracture and bone ... Keywords: Bone Density Conservation Agents, Geography, Medical, Hip Fractures, Osteoporosis. Full Text Order reprints Export ... Ex Vivo Evaluation of Hip Fracture Risk by Proximal Femur Geometry and Bone Mineral Density in Elderly Chinese Women. Xiao- ... to precisely estimate the risk of hip fracture by exploring the relationship between hip fracture and bone mineral density (BMD ...
Bone Density; Bone Density Conservation Agents; Denosumab; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; ... Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral ... Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. ... 19 more authors) (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for ...
... bone density conservation agents, acid-suppressive therapy, levothyroxine, thiazolidinediones (TZDs), selective serotonin ... Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the ... Bone 103, 116-124. Oct 2017. PMID 28666972. Bone fracture risk increases with age, disease states, and with use of certain ... Bergapten Promotes Bone Marrow Stromal Cell Differentiation Into Osteoblasts in Vitro and in Vivo JJ Xiao et al. Mol Cell ...
Bone Density Conservation Agents. 20. calcitonin. Interventional clinical trials:. #. Name. Status. NCT ID. Phase. Drugs. ... Affiliated tissues include lung, liver and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and ... The drugs Fibrinolytic Agents and Plasminogen have been mentioned in the context of this disorder. ...
Bone Density Conservation Agents. Not Applicable. 41. Vitamin D2. Nutraceutical. Not Applicable. ... Affiliated tissues include t cells, skin and bone, and related phenotype is neoplasm. ...
Bone Density Conservation Agents/adverse effects/*therapeutic use. Diphosphonates/therapeutic use. Female ... The accuracy of bone measurement tests to identify osteoporosis varied (area under the curve [AUC], 0.32-0.89). The pooled ... The accuracy of bone measurement tests or clinical risk assessments for identifying osteoporosis or predicting fractures varied ... bone measurement tests or clinical risk assessments, pharmacologic treatment. Data Extraction and Synthesis: Dual, independent ...
en] Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use ; Clinical Trials as Topic ; Drug Approval/ ... Recommendations for the registration of agents.pdf. No commentary. Publisher postprint. 89.46 kB. Request copy. ... Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update ... Reference : Recommendations for the registration of agents for prevention and treatment of glucoc.... ...
Bone Density Conservation Agents - Therapeutic Use. en_US. dc.subject.mesh. Diphosphonates - Adverse Effects - Therapeutic Use ... The primary endpoint was percentage change from baseline in lumbar spine bone mineral density. Drug efficacy was assessed on a ... The primary endpoint was percentage change from baseline in lumbar spine bone mineral density. Drug efficacy was assessed on a ... Findings: Zoledronic acid was non-inferior and superior to risedronate for increase of lumbar spine bone mineral density in ...
Bone Density Conservation Agents/administration & dosage*. *Calcium/administration & dosage*. *Hyperparathyroidism, Secondary/ ... Bottom Line: Bone turnover markers did not decrease.Calcium supplementation had no effect on serum PTH and bone turnover.Daily ... Bottom Line: Bone turnover markers did not decrease.Calcium supplementation had no effect on serum PTH and bone turnover.Daily ... Bone turnover markers did not decrease. Calcium supplementation had no effect on serum PTH and bone turnover. ...
  • and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma. (drugbank.ca)
  • Life expectancy from first diagnosis of breast cancer bone metastases is several years, during which time skeletal-related events - including pain, fracture, hypercalcemia, and spinal cord compression - significantly degrade quality of life. (iupui.edu)
  • Recent results from the Breast cancer trials of Oral Everolimus-2 trial suggest that agents such as the mammalian target of rapamycin inhibitor everolimus may have efficacy against breast cancer bone metastases in part via stimulating osteoblasts as well as by inhibiting tumor growth. (iupui.edu)
  • This review discusses the future role of bone-anabolic agents for the specific treatment of osteolytic breast cancer metastases. (iupui.edu)
  • Stimulation of osteoblast activity inhibits multiple myeloma growth - a strategy that might decrease breast cancer burden in osteolytic bone metastases. (iupui.edu)
  • A) After binding of Wnt to the LRP5/6 receptor, β-catenin translocates into the nucleus, binds to TCF/LEF transcription factors, and stimulates transcription of osteoblast genes, which results in enhanced bone formation. (nih.gov)
  • Genetic, biochemical, and histological analyses of this mutant and a comparison to a second, similar locus reveal that Bmp1a is critically required for mature-collagen generation, downstream of osteoblast maturation, in bone. (zfin.org)
  • There is now good evidence that dietary components and herbal products can influence these processes, particularly by inhibiting bone resorption, thus having beneficial effects on the skeleton. (isharonline.org)
  • Dual-energy X-ray absorptiometry (DXA) is a cornerstone of pediatric bone health assessment, yet differences in height-for-age confound the interpretation of areal bone mineral density (aBMD) measures. (bioportfolio.com)
  • Agents with both anti-tumor and bone-anabolic actions have been tested in the setting of multiple myeloma, a hematological malignancy that causes severe osteolytic bone loss and suppression of osteoblastic new bone formation. (iupui.edu)
  • The authors examined ONJ incidence in four additional clinical trials involving patients with osteopenia or OP who were treated with ZOL, and they analyzed levels of the bone resorption marker serum β C-telopeptide (S-CTx) to assess its usefulness in predicting the risk of developing ONJ. (duke.edu)
  • Osteoblastic functions and bone formation is reduced. (nih.gov)
  • C) Antibodies against sclerostin or DKK-1, or both, neutralise the Wnt inhibitors, thus restoring the scenario of unopposed Wnt signalling as depicted in panel A, which leads to enhanced osteoblastic bone formation. (nih.gov)
  • The continuous turnover of bone matrix and mineral that involves first, an increase in resorption (osteoclastic activity) and later, reactive bone formation (osteoblastic activity). (bioportfolio.com)
  • Proteasome inhibitors (bortezomib and carfilzomib) inhibit the growth of myeloma directly and are anabolic for bone. (iupui.edu)
  • D-003, a mixture of high molecular weight sugarcane wax acids, has been shown to inhibit cholesterol synthesis prior to mevalonate production, resulting in a reduction of bone loss and resorption in ovariectomized rats. (kjim.org)
  • For example, it has been reported that a number of common vegetables, including onion, garlic and parsley, can inhibit bone resorption in ovariectomized rats. (isharonline.org)
  • A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. (bioportfolio.com)
  • A continuous bone remodeling process that involves the balance between bone resorption and bone formation maintains the integrity of the mature adult skeleton. (kjim.org)
  • Transforming growth factor-beta inhibitors have little tumor antiproliferative activity but block breast cancer production of osteolytic factors and are also anabolic for bone. (iupui.edu)
  • Anabolic bone window with weekly teriparatide therapy in post menopaus" by Vinaya Gopalaswamy, Deba Prasad Dhibar et al. (henryford.com)
  • CONCLUSION: Weekly teriparatide therapy (60 μg) appears to be as effective as daily teriparatide for the treatment of PMO by extending the anabolic bone window. (henryford.com)
  • Combination therapy with ZOL plus ALF was more effective in decreasing bone porosity than each drug administered as monotherapy in RHLI rats . (bvsalud.org)
  • Moreover, combination therapy using ZOL plus ALF was more effective in improving dry bone and ash weight, than single- drug therapy using ZOL or ALF in RHLI rats . (bvsalud.org)
  • Fracture during oral bisphosphonate therapy is associated with deteriorated bone material strength index. (ox.ac.uk)
  • Patients were divided into two groups depending on whether or not they had prior bisphosphonate exposure, and the response to teriparatide was compared using procollagen of type 1 N-terminal propeptide (P1NP) and bone mineral density (BMD). (biomedsearch.com)
  • As such, there remains an important clinical need to develop ways to enhance patient acceptance and compliance with these effective drugs, and to continue to develop new drugs that do not cause these side-effects and have prolonged anabolic effects on bone. (nih.gov)
  • The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. (bioportfolio.com)
  • Decrease, loss, or removal of the mineral constituents of bones. (bioportfolio.com)
  • Temporary loss of bone mineral content is especially associated with space flight, weightlessness, and extended immobilization. (bioportfolio.com)
  • Background: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. (hku.hk)
  • Bone loss is the most devastating adverse effect of these powerful medications. (elsevier.com)
  • Disuse by bed rest , limb immobilization or space flight causes rapid bone loss. (bvsalud.org)